CIBC Asset Management
INO icon

CIBC Asset Management’s Inovio Pharmaceuticals INO Stock Holding History

CIBC Asset Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-860
Closed -$37K – 1374
2022
Q1 		$37K Hold
860
– – ﹤0.01% 1506
2021
Q4 		$51K Buy
+860
New +$68.9K ﹤0.01% 1522

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

CIBC Asset Management's INO Position: Q2 2022 in Review

CIBC Asset Management sold out of Inovio Pharmaceuticals (INO) in Q2 2022, closing a stake of 860 shares — an estimated $37K sold.

CIBC Asset Management first reported a position in INO in Q4 2021 and held it in 2 quarters. The position peaked at $51K in Q4 2021. 184 funds tracked by Wall St. Rank hold INO as of Q2 2022.

  • CIBC Asset Management reported no remaining Inovio Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • CIBC Asset Management sold 860 Inovio Pharmaceuticals shares in Q2 2022, an estimated $37K.
  • CIBC Asset Management first reported a position in Inovio Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • CIBC Asset Management's Inovio Pharmaceuticals position peaked at $51K in Q4 2021.
  • 184 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2022.

Based on CIBC Asset Management's 13F filing for Q2 2022, filed 9 Aug 2022.